Allogenic Anti-CD33 gamma delta CAR-T cell therapy (TC BioPharm)

N/A

Report date: 2022/11/02 11:30:07

Base Information

Drug NameAllogenic Anti-CD33 gamma delta CAR-T cell therapy (TC BioPharm)
Drug Alias NameAutologous Anti-CD33 CAR-T cell therapy (TC BioPharm)CD33-targetting chimeric antigen receptor γδ T cell therapy (TC BioPharm)Anti-CD33 CAR-γδT cell therapy (TC BioPharm)Anti-CD33 γδ CAR-T cell therapy (TC BioPharm)CD33 gamma-delta CAR-T cell therapy (TC BioPharm)
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicityAnti-Myeloid cell surface antigen CD33
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity College London
China Registration ClassN/A

Develop Information

Active CompaniesTc Biopharm Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A